Replies to post #151792 on Biotech Values

[wdr7]

It is University of Oxford study.
Official Title: A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma
http://clinicaltrials.gov/ct2/show/NCT01256359?term=selumetinib&cond=melanoma&phase=1&rank=4

Aztra Zeneca coducted different study.
Official Title: A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
http://clinicaltrials.gov/ct2/show/NCT00936221?term=selumetinib&cond=melanoma&phase=1&rank=6

Different BRAF mutation status, different primary endpoints.